Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Defactinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 known ✓ | Q05397 | 20/20 | 1.00 |
| ▸ | PTK2B known ✓ | Q14289 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | ERCC2 | P18074 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Defactinib SCHEMBL1626017 | 0.99 | PTK2 (0.98) | PTK2PTK2BAURKAJAK2STK16 | |
| Defactinib SCHEMBL23086796 | 0.94 | PTK2 (0.89) | PTK2PTK2BAURKAJAK2STK16 | |
| Defactinib SCHEMBL28419282 | 0.94 | PTK2 (0.89) | PTK2PTK2BAURKAJAK2STK16 | |
| SCHEMBL26126341 | 0.92 | PTK2 (0.86) | PTK2PTK2BAURKAJAK2STK16 | |
| SCHEMBL31653624 | 0.92 | PTK2 (0.86) | PTK2PTK2BAURKAJAK2STK16 | |
| SCHEMBL29853474 | 0.91 | PTK2 (1.00) | PTK2PTK2BAURKAJAK2STK16 | |
| SCHEMBL1627066 | 0.91 | PTK2 (1.00) | PTK2PTK2BAURKAJAK2STK16 | |
| Defactinib SCHEMBL23086969 | 0.91 | PTK2 (0.83) | PTK2PTK2BAURKAJAK2STK16 | |
| Defactinib SCHEMBL23701664 | 0.91 | PTK2 (0.83) | PTK2PTK2BAURKAJAK2STK16 | |
| SCHEMBL1626939 | 0.90 | PTK2 (1.00) | PTK2PTK2BAURKAJAK2STK16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137839-A1 | CONTROLLED HYDROGEL DELIVERY OF FOCAL ADHESION KINASE INHIBITOR FOR DECREASED SCAR FORMATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | US | claimed |
| EP-4096671-B1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4028010-B1 | VS-6063 IN COMBINATION WITH CH5126766 FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| US-20260034128-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2026-02-05 | — | — | US | claimed |
| US-12521394-B2 | Therapeutic compositions and methods for treating cancers | Pattern Computer, Inc. (US) | 2026-01-13 | — | — | US | claimed |
| EP-3999065-B1 | THERAPEUTIC COMPOSITIONS COMPRISING IDELALISIB AND DEFACTINIB FOR TREATING BREAST CANCERS | PATTERN COMPUTER INC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| US-20220040317-A1 | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-10 | — | — | US | claimed |
| US-20220031698-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-02-03 | — | — | US | claimed |
| EP-2146779-B1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2016-08-10 | — | — | EP | claimed |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2015-03-19 | — | — | US | claimed |
| US-8247411-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2012-08-21 | — | — | US | claimed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | claimed |
| EP-2146779-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | claimed |
| WO-2008129380-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2008-10-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885AURKA 1617/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885AURKA 1617/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PTK2 1/4885PTK2B 42/4885AURKA 173/4885 |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | CHRM1, CHRNA6, OPRM1 | PTK2 3024/4885PTK2B 3109/4885AURKA 1893/4885 |
| US-20220040317-A1 | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | ALK, PTK2, CBL | PTK2 2/4885PTK2B 30/4885AURKA 780/4885 |
| US-20260137839-A1 | CONTROLLED HYDROGEL DELIVERY OF FOCAL ADHESION KINASE INHIBITOR FOR DECREASED SCAR FORMATION | PTK2, DSTYK, CTTN | PTK2 1/4885PTK2B 5/4885AURKA 806/4885 |
| US-20260034128-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CTTN, MAP2K2 | PTK2 1/4885PTK2B 9/4885AURKA 1134/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885AURKA 1617/4885 |
| US-20220031698-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | BRAF, PTK2, NRAS | PTK2 2/4885PTK2B 120/4885AURKA 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.